Multi-Omics Biomarker Panels for MASLD Subtype Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high heterogeneity of metabolic dysfunction-associated fatty liver disease (MASLD) poses challenges for accurate classification and targeted treatment, with existing drugs like Resmetirom showing limited efficacy due to species differences and patient variability.
Innovation Solution
A biomarker combination system is developed, comprising liver and serum protein, lipid, and metabolite markers, to classify MASLD into metabolically active, high-risk cirrhosis, and high-risk hepatocellular carcinoma types, providing a foundation for personalized treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single drug treatment approach is used for all MASLD patients, then treatment simplicity is maintained, but therapeutic efficacy is reduced due to high disease heterogeneity
Solution Approach 1:
The patent segments MASLD patients into three distinct molecular subtypes (metabolically active, high-risk cirrhosis, high-risk HCC) based on molecular characteristics. This segmentation allows for targeted treatment strategies tailored to each subtype, improving therapeutic efficacy while managing complexity through systematic classification.
Solution Approach 2:
The patent uses changes in molecular parameters (gene expression profiles, protein levels, metabolite concentrations) to define and differentiate MASLD subtypes. By monitoring these parameter changes, the system identifies distinct patient groups that respond differently to treatments, enabling more effective therapeutic decisions.
2Measurement precision
If comprehensive multi-omics biomarker analysis is implemented, then classification accuracy is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent merges multiple omics layers (transcriptomics, proteomics, metabolomics) into an integrated molecular classification system. By combining these different types of biomarker data, the system achieves higher classification accuracy for MASLD subtypes than any single omics layer could provide alone.
Solution Approach 2:
The patent develops a universal molecular classification framework that can be applied across different MASLD patient populations and clinical settings. The multi-omics biomarker panel serves multiple functions including diagnosis, prognosis, and treatment selection, maximizing the utility of the diagnostic system.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An application of a biomarker in preparing metabolic dysfunction-associated steatotic liver disease classification products is provided, which belongs to the technical field of biomarkers.. The biomarker is any one or more of the following: a combination of liver protein biomarkers, a combination of serum protein biomarkers, a combination of serum lipid biomarkers, a combination of serum metabolite biomarkers, a combination of serum multiomics (including protein, lipid and metabolite) biomarkers, a combination of urine protein biomarkers, a combination of urine metabolite biomarkers, and a combination of urine multiomics (including protein and metabolite) biomarkers; and the metabolic dysfunction-associated steatotic liver disease is divided into a metabolically active type, a high-risk type of cirrhosis and a high-risk type of hepatocellular carcinoma. The combinations of biomarkers provided by the present disclosure have a good effect on the diagnosis of three MASLD molecular subtypes, which provides technical support for the classification and diagnosis of MASLD.